 |
| Issue 11, 31 August 2007
|
Dear Shareholders
Welcome to the latest edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments.
If you would like any further information, please contact us.
Regards
John Priest - CEO |
|
|
|
 |
Apollo Signs Major Supply Agreement with US Giant
This month (August) Apollo Life Sciences announced it has entered into a supply agreement with a leading US provider of products to the international biopharmaceutical industry. Apollo will supply Millipore Corporation in the US with human Leukaemia Inhibitory Factor (hLIF) for resale in worldwide markets. The announcement of the agreement has been covered widely in the international industry media, including the highly regarded BioWorld Today and The Life Science Executive Exchange.
LIF is a patented protein that is used to maintain stem cells in an undifferentiated state, prior to their maturation into specialized cells such as insulin-producing cells or heart muscle cells. Apollo's Head of Sales and Marketing for its protein business, Leanne Daly, said the boom in stem cell research, and its inevitable move towards stem cell therapies, means that there will be a rapidly growing need for high potency human LIF to maintain embryonic stem cells in culture. |
|
|
|
As Arthritis Costs Soar, the Need for Therapies Also Skyrockets
With the release of a new report revealing that arthritis costs the health system more than $4 billion a year, there is increased attention on the need for better drugs to treat the disease. The report has again highlighted the importance of Apollo's research into developing an oral pain treatment for arthritis. |
|
Apollo’s Insulin Tablet Makes the News
Apollo continued to attract attention with its oral insulin – with an article in the national magazine, The Bulletin. The article, appearing in one of Australia’s best business journals, means that Apollo is on the radar. |
|
| Click here to subscribe |
 |
| www.apollolifesciences.com |